vs
NEOGENOMICS INC（NEO）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是NEOGENOMICS INC的1.0倍（$188.3M vs $186.7M），BRC Group Holdings, Inc.净利率更高（47.9% vs -57.9%，领先105.8%），NEOGENOMICS INC同比增速更快（11.1% vs -21.9%），过去两年NEOGENOMICS INC的营收复合增速更高（6.5% vs -15.4%）
新基因组公司（NeoGenomics）是美国一家经CLIA认证的临床实验室企业，提供药企服务与信息服务，专注于癌症基因诊断检测，旗下检测服务涵盖细胞遗传学、荧光原位杂交（FISH）、流式细胞术、免疫组化、解剖病理学及分子遗传学等多个领域，为肿瘤相关诊断提供专业支持。
NEO vs RILY — 直观对比
营收规模更大
RILY
是对方的1.0倍
$186.7M
营收增速更快
NEO
高出33.0%
-21.9%
净利率更高
RILY
高出105.8%
-57.9%
两年增速更快
NEO
近两年复合增速
-15.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $186.7M | $188.3M |
| 净利润 | $-108.0M | $90.3M |
| 毛利率 | 43.3% | 79.5% |
| 营业利润率 | 46.9% | 32.3% |
| 净利率 | -57.9% | 47.9% |
| 营收同比 | 11.1% | -21.9% |
| 净利润同比 | 42.0% | 1710.8% |
| 每股收益（稀释后） | $-0.13 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NEORILY
| Q1 26 | $186.7M | — | ||
| Q4 25 | $190.2M | $188.3M | ||
| Q3 25 | $187.8M | $215.3M | ||
| Q2 25 | $181.3M | $188.2M | ||
| Q1 25 | $168.0M | $197.2M | ||
| Q4 24 | $172.0M | $241.0M | ||
| Q3 24 | $167.8M | $225.5M | ||
| Q2 24 | $164.5M | $256.0M |
净利润NEORILY
| Q1 26 | $-108.0M | — | ||
| Q4 25 | — | $90.3M | ||
| Q3 25 | $-27.1M | $91.1M | ||
| Q2 25 | $-45.1M | $139.5M | ||
| Q1 25 | $-25.9M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $-17.7M | $-284.4M | ||
| Q2 24 | $-18.6M | $-433.6M |
毛利率NEORILY
| Q1 26 | 43.3% | — | ||
| Q4 25 | 43.8% | 79.5% | ||
| Q3 25 | 42.8% | 83.7% | ||
| Q2 25 | 42.6% | 81.3% | ||
| Q1 25 | 43.6% | 81.4% | ||
| Q4 24 | 44.9% | 79.8% | ||
| Q3 24 | 44.6% | 82.1% | ||
| Q2 24 | 44.1% | 84.5% |
营业利润率NEORILY
| Q1 26 | 46.9% | — | ||
| Q4 25 | -7.1% | 32.3% | ||
| Q3 25 | -14.4% | 30.4% | ||
| Q2 25 | -26.3% | 5.7% | ||
| Q1 25 | -16.6% | -31.2% | ||
| Q4 24 | -10.7% | -69.2% | ||
| Q3 24 | -12.6% | -36.4% | ||
| Q2 24 | -13.3% | -90.8% |
净利率NEORILY
| Q1 26 | -57.9% | — | ||
| Q4 25 | — | 47.9% | ||
| Q3 25 | -14.4% | 42.3% | ||
| Q2 25 | -24.9% | 74.1% | ||
| Q1 25 | -15.4% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -10.5% | -126.1% | ||
| Q2 24 | -11.3% | -169.4% |
每股收益（稀释后）NEORILY
| Q1 26 | $-0.13 | — | ||
| Q4 25 | — | $2.78 | ||
| Q3 25 | — | $2.91 | ||
| Q2 25 | — | $4.50 | ||
| Q1 25 | — | $-0.39 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | — | $-9.39 | ||
| Q2 24 | — | $-14.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.1M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $828.8M | $-171.5M |
| 总资产 | $1.3B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NEORILY
| Q1 26 | $146.1M | — | ||
| Q4 25 | $159.6M | $226.6M | ||
| Q3 25 | $164.1M | $184.2M | ||
| Q2 25 | $154.7M | $267.4M | ||
| Q1 25 | $346.2M | $138.3M | ||
| Q4 24 | $367.0M | $146.9M | ||
| Q3 24 | $362.0M | $159.2M | ||
| Q2 24 | $355.1M | $236.9M |
总债务NEORILY
| Q1 26 | — | — | ||
| Q4 25 | $341.9M | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | $541.1M | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益NEORILY
| Q1 26 | $828.8M | — | ||
| Q4 25 | $836.6M | $-171.5M | ||
| Q3 25 | $838.3M | $-260.5M | ||
| Q2 25 | $854.0M | $-351.7M | ||
| Q1 25 | $888.3M | $-496.8M | ||
| Q4 24 | $902.3M | $-488.2M | ||
| Q3 24 | $908.2M | $-497.6M | ||
| Q2 24 | $915.9M | $-218.3M |
总资产NEORILY
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.6B | $2.2B | ||
| Q2 24 | $1.6B | $3.2B |
负债/权益比NEORILY
| Q1 26 | — | — | ||
| Q4 25 | 0.41× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.60× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.1M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流NEORILY
| Q1 26 | $-8.1M | — | ||
| Q4 25 | $1.3M | $26.2M | ||
| Q3 25 | $8.9M | $-60.6M | ||
| Q2 25 | $20.3M | $-25.6M | ||
| Q1 25 | $-25.3M | $184.0K | ||
| Q4 24 | $9.8M | $-2.7M | ||
| Q3 24 | $9.2M | $19.5M | ||
| Q2 24 | $13.9M | $111.5M |
自由现金流NEORILY
| Q1 26 | — | — | ||
| Q4 25 | $-6.5M | — | ||
| Q3 25 | $570.0K | — | ||
| Q2 25 | $14.0M | — | ||
| Q1 25 | $-29.8M | — | ||
| Q4 24 | $-1.8M | — | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | $814.0K | — |
自由现金流率NEORILY
| Q1 26 | — | — | ||
| Q4 25 | -3.4% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | -17.8% | — | ||
| Q4 24 | -1.0% | — | ||
| Q3 24 | -0.9% | — | ||
| Q2 24 | 0.5% | — |
资本支出强度NEORILY
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | — | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.7% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 6.4% | — | ||
| Q2 24 | 8.0% | — |
现金转化率NEORILY
| Q1 26 | — | — | ||
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NEO
暂无分部数据
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
